Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year

Core Insights - Intelligent Bio Solutions Inc. anticipates record revenue growth for fiscal Q2 2026, driven by an expanding customer base and strong performance across all product categories [1][2] - Reader sales are expected to more than double year-over-year, with a growth rate exceeding 100% in fiscal Q2 [1][2] - The company emphasizes a razor-razorblade business model, where each reader placement fosters long-term relationships that generate recurring cartridge revenue [2] Revenue Expectations - Total revenue for fiscal Q2 2026 is projected to be approximately $2.01 million, reflecting a 36% year-over-year increase [5] - Cartridge sales are expected to rise by approximately 38% year-over-year, while reader sales are anticipated to increase by about 50% year-over-year [5] - Other sales, including accessories and training, are expected to grow by approximately 10% year-over-year [5] Business Model and Strategy - The anticipated 33% growth in cartridge sales illustrates the effectiveness of the company's business model, highlighting new customer adoption and ongoing demand for consumables [2] - The company is confident in its commercial strategy and aims to capture greater market share as its installed reader base expands [2] - The Intelligent Fingerprinting Drug Screening System is positioned to revolutionize portable testing through rapid, non-invasive methods, targeting various industries such as construction and logistics [3]